| 651 |
24085367 | [Chemotherapy-free treatment of chronic lymphocytic leukemia?]. | 2013 Oct |
2 |
| 652 |
24103588 | Molecular bases of chronic lymphocytic leukemia in light of new treatments. | 2013 Sep-Oct |
2 |
| 653 |
24111579 | Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. | 2013 Nov |
3 |
| 654 |
24156429 | [Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms]. | 2013 Oct |
1 |
| 655 |
24433470 | Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition. | 2013 Dec |
2 |
| 656 |
22180443 | The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. | 2012 Feb 2 |
1 |
| 657 |
22279054 | The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. | 2012 Mar 15 |
3 |
| 658 |
22698399 | Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. | 2012 Jun 12 |
1 |
| 659 |
22960555 | Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. | 2012 Nov |
1 |
| 660 |
21422473 | Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | 2011 Jun 9 |
1 |
| 661 |
21752263 | The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. | 2011 Jul 13 |
3 |
| 662 |
21782064 | Molecular targeted approaches in mantle cell lymphoma. | 2011 Jul |
1 |
| 663 |
22131884 | Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma. | 2011 Nov |
3 |
| 664 |
20615965 | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. | 2010 Jul 20 |
1 |